Results of OCT STEMI Trial Reported at TCT 2014

WASHINGTON, DC – September 14, 2014 – The first randomized trial to examine serial optical coherence tomography (OCT) in primary percutaneous coronary intervention (PCI) was reported today at the 26th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world’s premier educational meeting specializing in interventional cardiovascular medicine.

OCT uses light emitted from an intravascular catheter to capture high-resolution cross sectional imaging from within coronary arteries. OCT STEMI is the first randomized multicenter study to examine routine use of OCT guidance during stent implantation in patients with ST-elevation myocardial infarction (STEMI, the most serious form of a heart attack) undergoing primary PCI. The primary endpoints were the rate of major adverse coronary events (MACE) including death, myocardial infarction, and ischemia-driven target lesion revascularization at 30 days and nine months. The number of uncovered struts, area stenosis and minimal lumen diameter assessed by OCT after nine months was also assessed.

A total of 201 patients were enrolled in the study and pre-treated with aspirin, heparin and clopidogrel. After radial diagnostic angiography, patients were randomly assigned to either primary PCI alone (n=96) or to primary PCI with OCT guidance (n=105). Drug-eluting stents (DES) were used in this trial and dual antiplatelet therapy was recommended for 12 months in both groups.

Baseline demographic and procedural characteristics were well balanced in both groups. Based on the OCT data, more stents were used in the OCT group (likely based upon the intraprocedural OCT findings), and fluoroscopy time was significantly longer in the OCT group.

The rate of MACE was very low and comparable at 30 days and nine-month follow up in both groups. The rates of stent thrombosis, late lumen loss and binary restenosis were also similarly low in both groups. Nine-month OCT analysis revealed significantly smaller area stenosis (p=0.001) and a trend toward fewer uncovered struts (p=0.07) in the OCT guided group. 

“The OCT STEMI trial demonstrates the potential merit of OCT guidance during drug-eluting stent implantation in primary PCI,” said lead investigator Pavel Cervinka, PhD, MD. Dr. Cervinka is a Professor from Faculty Hospital Hradee Králové and Masaryk Hospital in the Czech Republic.

“The study also indicates that the procedure is safe for STEMI patients, and larger randomized trials with longer-term follow-up are warranted.”

The OCT STEMI trial was funded by grants from Boston Scientific and A Care. Dr. Cervinka reported no disclosures.  

Press Contacts

Irma Damhuis
Director, External Relations
Tel: 646-434-4690

Judy Romero
Senior Manager, External Relations
Tel: 646-434-4608
press@crf.org